Blog

The European healthcare technology and medical technology sectors have reached a definitive inflection point in 2026, transitioning from a decade of speculative, venture-subsidised experimentation to an era of disciplined industrial maturity.This transformation is characterised by a fundamental shift away from the liquidity-fueled exuberance of the early 2020s toward a metrics-driven environment where strategic value is defined by clinical utility, regulatory resilience, and technological defensibility.&nbsp;Central to this transition is the emergence of the "Founder Banker," a new class of corporate financial advisor and entrepreneur who combines deep operational pedigree, having built, scaled and exited their own ventures, with sophisticated investment banking and private equity expertise. These individuals occupy a critical niche in the contemporary M&amp;A landscape, bridging the widening gap between digital economy metrics and the complex, often opaque, regulatory realities of modern healthcare systems.Banker-Founders: The Professionalisation of Healthtech LeadershipThe new wave of competitive advantage is increasingly driven by founders who moved from the upper echelons of corporate finance into Healthtech leadership. These individuals bring a level of "financial engineering" and strategic long-termism that traditional clinician-founders often struggle to replicate.Ali Parsa: From Goldman Sachs to Babylon HealthParsa's financial background was instrumental in Babylon’s ability to attract unprecedented levels of capital, including a $550 million funding round in 2019 backed by Saudi Arabia's Public Investment Fund.Stanislas Niox-Chateau: The Strategist Behind DoctolibIn France, Stanislas Niox-Chateau has demonstrated a more industrially disciplined approach to the banker-founder model.Johannes Schildt: Finance and the Scaling of Kry/LiviCo-founder and CEO of the Swedish digital health giant Kry (known as Livi in France and the UK), similarly leverages a background at Stifel Financial Corp to navigate the capital-intensive digital health landscape.Jean-Charles Samuelian-Werve: The Systems Thinker at AlanAt Alan, he has rebuilt health insurance from the ground up, scaling to over 500,000 members and a $4 Billion valuation.For founders, the emergence of the "Founder Banker" provides a vital roadmap to liquidity, offering the "operational empathy" required to navigate the Series A and B Crunches and achieve high-value exits.To read the full report, click here <a href="https://www.healthcare.digital/single-post/founder-bankers-and-banker-founders-new-competitive-advantages-in-european-healthtech-and-medtech">https://www.healthcare.digital/single-post/founder-bankers-and-banker-founders-new-competitive-advantages-in-european-healthtech-and-medtech</a>

Founder Bankers and Banker Founders: New Competitive Advantages in European HealthTech and MedTech

Nelson Advisors has been referenced in the Expert Opinions on Digital Health Innovations series - 'Exploration of Digital Health Technologies' within the &nbsp;'A call for responsible innovation in pediatric health care' publication.Source: <a href="https://www.explorationpub.com/Journals/edht/Special_Issues/365" data-mce-href="https://www.explorationpub.com/Journals/edht/Special_Issues/365">https://www.explorationpub.com/Journals/edht/Special_Issues/365</a>About the Special lssue This special issue seeks to gather expert opinions from a multidisciplinary group, including scientists, scholars, clinicians, bioengineers, and industry leaders, on the transformative potential of digital health innovations. We aim to explore how these technologies are reshaping healthcare delivery, patient outcomes, and clinical practices across diverse specialties, including geriatrics, orthopedics, general surgery, dentistry, genetics, and other fields.Submissions are encouraged to address the following themes:Impact of digital health innovations on clinical practice: How are emerging technologies, such as artificial intelligence, telemedicine, wearables, and mobile health applications, influencing diagnosis, treatment, and patient management in specific specialties? Patient perspectives: How are patients experiencing and engaging with digital health tools? What are the benefits and challenges of these technologies from patients’ point of view? Ethical, legal, and social implications (ELSI): What are the ethical considerations surrounding data privacy, security, and algorithmic bias in the context of digital health? How can we ensure equitable access to these innovations? Future directions and challenges: What are the most promising avenues for future research and development in digital health? What barriers and challenges need to be overcome to realize the full potential of these technologies? We invite original research articles, reviews, case studies, and perspectives that shed light on the current state and future trajectory of digital health innovations, providing valuable insights for clinicians, researchers, policymakers, and industry stakeholders.A call for responsible innovation in pediatric health careExplor Digit Health Technol. 2026;4:101178 DOI: https://doi.org/10.37349/edht.2026.101178Received: September 01, 2025 Accepted: November 17, 2025 Published: January 06, 2026Academic Editor: Marco Tatullo, University of Bari, ItalyThe article belongs to the special issue Expert Opinions on Digital Health InnovationsSource: <a href="https://www.explorationpub.com/Journals/edht/Article/101178">https://www.explorationpub.com/Journals/edht/Article/101178</a>

Nelson Advisors referenced in the Expert Opinions on Digital Health Innovations series - 'Exploration of Digital Health Technologies'

Nelson Advisors partner Lloyd Price has been acknowledged in the Exploration of Digital Health Technologies publication 'A call for responsible innovation in pediatric health care.'Source: <a href="https://www.explorationpub.com/Journals/edht/Article/101178" data-mce-href="https://www.explorationpub.com/Journals/edht/Article/101178">https://www.explorationpub.com/Journals/edht/Article/101178</a>AcknowledgmentsWe gratefully acknowledge Lloyd Price, BA (Hons.), Partner at Nelson Advisors LLP, London, UK, for his editorial feedback and comments on early drafts of this manuscript.A call for responsible innovation in pediatric health careArtificial intelligence (AI) is transforming healthcare by equipping clinicians and patients with tools that support more efficient, patient-centered care. In pediatrics, however, the implementation of AI demands a higher threshold for responsibility, transparency, and family-centered engagement. This perspective explores the opportunities and challenges of AI in pediatric healthcare, highlighting the unique ethical and developmental considerations that distinguish children’s care from adult medicine. Drawing on Kaiser Permanente’s seven principles for responsible AI, the article emphasizes the importance of augmentation over automation, the need for pediatric-specific validation, and the necessity of trustworthiness and fairness in clinical deployment. It outlines how AI can support primary care providers through enhanced decision support, early screening for developmental and behavioral disorders, including the potential for AI to create personalized developmental trajectories, moving beyond static population norms to provide earlier, more precise insights into a child’s neurodevelopmental progress, improved electronic health record usability, and risk prediction models. However, without careful governance, AI poses risks of bias, inequity, and erosion of clinician judgment. Policy recommendations include redesigning family consent models, ensuring robust clinician training, and mandating pediatric-specific testing of AI systems with diverse, representative datasets. Ultimately, AI should function as a supportive tool that strengthens, not replaces, human empathy, clinical expertise, and family-centered values. Responsible innovation is essential to ensure that children benefit equitably from AI while maintaining trust, safety, and compassion in pediatric healthcare.

Nelson Advisors acknowledged in the Exploration of Digital Health Technologies publication

Nelson Advisors has been referenced by Clear Capital Markets in their 'MedPal AI: Looking to bulk up the price on weight-loss drive' Broker Note.Source: <a href="https://www.clearcapitalmarkets.co.uk/analysis/medpal-ai-broker-note" data-mce-href="https://www.clearcapitalmarkets.co.uk/analysis/medpal-ai-broker-note">https://www.clearcapitalmarkets.co.uk/analysis/medpal-ai-broker-note</a>Valuations Medpal EV/Revenue multiple of between 6-8x for the 1Y forward period37“Dominance of AI and Digital Health: AI is the single biggest driver of valuation premiums. Investors and strategic buyers are focusing on companies with proprietary AI algorithms for diagnostics, drug discovery, or patient care. They are particularly interested in solutions that have been clinically validated and are deeply integrated into existing clinical workflows, creating "workflow lock-in."” Nelson Advisers.Note 37 <a href="https://nelsonadvisors.co.uk/blog/european-medtech-valuation-multiples---september-2025">https://nelsonadvisors.co.uk/blog/european-medtech-valuation-multiples---september-2025</a> &nbsp;nelsonadvisors.co.uk/blog/european-medtech-valuation-multiples---september-2025Clear Capital MarketsClear Capital Markets is a proud member of the London Stock Exchange Authorised and regulated by the Financial Conduct Authority. FRN: 706689AI × Robotic Powered Healthcare Ecosystem&nbsp; Sometimes there are businesses where the plan is so in the sweet spot and the management is so focused on the opportunity that they progress at a speed which the market at large confuses with a mixed message.Medpal AI from inception was always about creating a powerful Telehealth vertical and they spotted the opportunity, and grasped it, to enter into the clinical dispensing layer of the healthcare model with the Universal Pharmacy deal4.From inception, and reviewing their business at IPO, it was obvious to us that MPAL is at the cutting edge of the AI interface. They are all about disrupting models but with a purpose. Too many devices, apps, fragmented data. Healthcare markets and insurers disjointed, all in an era where information and science have never been so prolific and advanced.The UK market for health is broken. Speak to most people about the NHS system and trying to access their doctor and the lucky ones will have an appointment in two weeks time. Pharmacies are closing or going out of business (over 1,000 since 202638). Manual dispensing has a 2% error rate and chronic disease management is an after thought. This is why the online pharmacy /Telehealth model is growing so quickly.The first incarnation of Medpal had already identified the data disconnect problem. 1.4bn people globally using digital health tools40, with over 50% of UK adults owning a wearable device41 but with so few joined options where the data leads you down the chain to healthcare delivery. Medpal would look to solve this with the app that was device and operating system agnostic and partnerships to move you down the vertical to telehealth practitioners.Medpal has evolved significantly in a short space of time. The goal of making wellness and healthcare instantly accessible and affordable for everyone is still the aim and with a focus on rebuilding the UK system. They should be at the front end of this as they have actually moved down the vertical and are focused on patient interaction now. Effectively they are now solving patient healthcare needs and reversing them into health management. The technology platform combined with robotic automation puts Medpal in the upper quadrant of offerings and built to outperform at scale.&nbsp;The routes to the MedPal ecosystem have expanded beyond the app to medpal.clinic and WhatsApp interaction with a clinician-trained AI.Focusing data and behaviours into a centralised dispensing model with 24/7 clinical support and delivery nationwide within a day. They have reached incredible scale in a short time without short-cuts in a regulated health market trying its best to remove bad actors whilst improving customer outcomes.

Nelson Advisors referenced by Clear Capital Markets in their MedPal AI Broker Note

The global healthcare landscape in 2030 is defined by a paradigm shift from reactive, episode-based care to proactive, continuous health management facilitated by the industrialisation of artificial intelligence. At the vanguard of this transformation is Anthropic’s Claude ecosystem, which has successfully transitioned from a collection of generative models into a foundational clinical infrastructure.&nbsp; &nbsp;&nbsp; The trajectory of this development was dictated not merely by increases in raw computational power, but by a strategic emphasis on safety-first alignment, interoperability through open standards and a deep integration into the regulated workflows of life sciences and clinical practice.&nbsp; &nbsp;&nbsp; By 2030, the healthcare AI market, which was valued at approximately $36.67 Billion in 2025, has expanded at a compound annual growth rate (CAGR) of nearly 39% as health systems reallocate capital toward platforms that demonstrate recurring value through clinical defensibility and administrative throughput.The integration of Anthropic’s Claude into the 2030 healthcare ecosystem represents more than a technological upgrade; it is the realisation of a patient-centred, data-driven medical frontier. By positioning itself as the "Safety-first" partner for regulated industries, Anthropic has moved beyond the "inference resale" model to become an indispensable layer of the modern clinic.&nbsp; &nbsp;&nbsp; The focus on Constitutional AI has provided the necessary guardrails for high-stakes decision-making, while open standards like MCP have dissolved the silos that once paralysed medical data. &nbsp;&nbsp; As we look toward the 2030s, the challenge for healthcare leaders is no longer to adopt AI faster but to build the organizational capabilities required to sustain and scale it safely. The winners of this era are those who have successfully integrated AI into their core workflows, transforming it from a novelty into a "brilliant friend" with the knowledge of a doctor and the precision of a computer.&nbsp; &nbsp;&nbsp; In this environment, Claude serves not as a replacement for human judgment but as its most powerful amplifier, ensuring that the complexity of human biology is navigated with intelligence, empathy, and an unwavering commitment to safety.Click here to read our Blog Post <a href="https://www.healthcare.digital/single-post/the-orchestration-of-clinical-intelligence-anthropic-claude-and-the-healthcare-ecosystem-in-2030">https://www.healthcare.digital/single-post/the-orchestration-of-clinical-intelligence-anthropic-claude-and-the-healthcare-ecosystem-in-2030</a>Nelson AdvisorsTo discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Anthropic Claude and the Healthcare Ecosystem in 2030

Nelson Advisors have been invited to the House of Commons for the launch of the UCL GBSH Societal Impact Report on May 6th 2026.Hosted by Baroness Gisela Stuart, the evening will showcase the achievements of UCL Global Business School for Health in advancing its mission and vision across education, research, innovation and partnership.It will also recognise the organisations and some of the individuals whose collaboration has helped make that progress possible, while looking ahead to the next chapter of impact in global healthcare.Source: <a href="https://www.linkedin.com/posts/uclgbsh-healthcareleadership-globalhealth-share-7455287187753025536-tXBu/">https://www.linkedin.com/posts/uclgbsh-healthcareleadership-globalhealth-share-7455287187753025536-tXBu/</a>The UCL Global Business School for Health (GBSH) is the first business school in the world totally dedicated to health and healthcare management. Established in 2021, it was born out of the realisation, amplified by the COVID-19 pandemic, that health systems worldwide desperately need better leadership, management, and innovation to remain sustainableSource: <a href="https://www.ucl.ac.uk/population-health-sciences/global-business-school-health">https://www.ucl.ac.uk/population-health-sciences/global-business-school-health</a>

Nelson Advisors

Blog

Founder Bankers and Banker Founders: New Competitive Adva...

Nelson Advisors referenced in the Expert Opinions on Digi...

Nelson Advisors acknowledged in the Exploration of Digita...

Nelson Advisors referenced by Clear Capital Markets in th...

Anthropic Claude and the Healthcare Ecosystem in 2030

Nelson Advisors have been invited to the House of Commons...